Antigen-coupled immunoreagents
The present disclosure provides high-performance immunoreagents for use in a variety of immunologic assays and other related techniques. The immunoreagents comprise a primary antibody and a bridging antigen, wherein the bridging antigen is recognized by a detectable secondary antibody with high affinity. Also provided are compositions comprising panels of immunoreagents specific for multiple different target antigens and compositions comprising pairs of primary immunoreagents and their complementary detectable secondary antibodies. The paired primary immunoreagents and secondary antibodies are useful in a variety of immunologic assays, particularly in highly multiplexed assays, where the structure of the bridging antigen is varied in tandem with variation in the detectable secondary antibody, such that a multiplicity of immunoreagents are provided that are capable of simultaneously detecting a multiplicity of target antigens in a single assay. Also provided are kits comprising the immunoreagents, methods of immunologic assay using the immunoreagents of the disclosure, and methods of preparation of the immunoreagents.
1. An immunoreagent composition comprising:
a primary antibody coupled to a bridging antigen, said bridging antigen comprising a peptide consisting of a sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8; and
a detectable secondary antibody;
wherein the detectable secondary antibody is a rabbit monoclonal antibody specific for said peptide.
2. The immunoreagent composition of claim 1 , wherein the bridging antigen comprises a plurality of copies of said peptide.
3. The immunoreagent composition of claim 2 , wherein the plurality of copies of said peptides are arranged in a linear repeating structure.
4. The immunoreagent composition of claim 2 , wherein the bridging antigen comprises a branched structure.
5. The immunoreagent composition of claim 1 , wherein the primary antibody and the bridging antigen are coupled by a chemical coupling reaction through a conjugation moiety.
6. The immunoreagent of claim 5 , wherein the primary antibody and the bridging antigen are coupled through a high-efficiency conjugation moiety that is at least 50% efficient in coupling the primary antibody and the bridging agent.
7. The immunoreagent composition of claim 6 , wherein the high-efficiency conjugation moiety is a Schiff base.
8. The immunoreagent composition of claim 7 , wherein the Schiff base is a hydrazone or an oxime.
9. The immunoreagent composition of claim 6 , wherein the high-efficiency conjugation moiety is formed by a click reaction.
10. The immunoreagent composition of claim 5 , wherein the conjugation moiety comprises a cleavable linker.
11. The immunoreagent composition of claim 1 , wherein the primary antibody is specific for a cellular marker.
12. The immunoreagent composition of claim 11 , wherein the cellular marker is selected from the group consisting of: 4-1BB, AFP, ALK1, Amyloid A, Amyloid P, Androgen Receptor, Annexin Al, ASMA, BCA225, BCL-1, BCL-2, BCL-6, BerEP4, Beta-Catenin, Beta-HCG, BG-8, BOB-1, CA19-9, CA125, Calcitonin, Caldesmon, Calponin-1, Calretinin, CAM 5.2, CD1a, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD15, CD19, CD20, CD21, CD22, CD23, CD25, CD30, CD31, CD33, CD34, CD38, CD42b, CD43, CD45 LCA, CD45RO, CD56, CD57, CD61, CD68, CD79a, CD99, CD117, CD138, CD163, CDX2, CEA, Chromogranin A, CMV, c-kit, c-MET, c-MYC, Collagen Type IV, Complement 3c (C3c), COX-2, CXCR5, CK1, CK5, CK6, CK7, CK8, CK14, CK18, CK17, CK19, CK20, CK903, CK AE1, CK AE1/AE3, D2-40, Desmin, DOG-1, E-Cadherin, EGFR, EMA, ER, ERCC1, Factor VIII-RA, Factor XIIIa, Fascin, FoxP1, FoxP3, Galectin-3, GATA-3, GCDFP-15, GCET1, GFAP, Glycophorin A, Glypican 3, Granzyme B, HBME-1, Helicobacter Pylori , Hemoglobin A, Hep Par 1, HER2, HMB-45, HSV I/II, ICOS, IFNgamma, IgA, IgD, IgG, IgM, IL17, IL4, Inhibin, iNOS, Kappa Ig Light Chain, Ki67, LAG-3, Lambda Ig Light Chain, Lysozyme, Mammaglobin A, MART-1/Melan A, Mast Cell Tryptase, MLH1, MOC-31, MPO, MSA, MSH2, MSH6, MUC1, MUC2, MUM1, MyoD1, Myogenin, Myoglobin, Napsin A, Nestin, NSE, Oct-2, OX40, OX40L, p16, p21, p27, p40, p53, p63, p504s, PAX-5, PAX-8, PD-1, PD-L1, PHH3, PIN-4, PLAP, PMS2, Pneumocystis jiroveci ( carinii ), PR, PSA, PSAP, RCC, S-100, SMA, SMM, Smoothelin, SOX10, SOX11, Surfactant Apoprotein A, Synaptophysin, TAG 72, TdT, Thrombomodulin, Thyroglobulin, TIA-1, TIM3, TRAcP, TTF-1, Tyrosinase, Uroplakin, VEGFR-2, Villin, Vimentin, and WT-1.
13. The immunoreagent composition of claim 1 , wherein the primary antibody is specific for an immunoglobulin from a different species.
14. The immunoreagent composition of claim 1 , wherein the detectable secondary antibody comprises a detectable label.
15. The immunoreagent composition of claim 14 , wherein the detectable label is a fluorophore, an enzyme, an upconverting nanoparticle, a quantum dot, or a detectable hapten.
16. The immunoreagent composition of claim 15 , wherein the detectable label is a fluorophore.
17. The immunoreagent composition of claim 15 , wherein the enzyme is a peroxidase, an alkaline phosphatase, or a glucose oxidase.
18. The immunoreagent composition of claim 17 , wherein the peroxidase is a horseradish peroxidase or a soybean peroxidase.
19. The immunoreagent composition of claim 1 , wherein the bridging antigen comprises a detectable label.
20. The immunoreagent composition of claim 19 , wherein the detectable label of the bridging antigen is a fluorophore.
21. The immunoreagent composition of claim 19 , wherein the detectable secondary antibody comprises a detectable label.
22. The immunoreagent composition of claim 21 , wherein the detectable label of the bridging antigen and the detectable label of the secondary antibody are both detectable by fluorescence at the same wavelength.
23. The immunoreagent composition of claim 1 , wherein the detectable secondary antibody is specific for the bridging antigen with a dissociation constant of at most 1 nM.
24. The immunoreagent composition of claim 1 , said secondary antibody having a dissociation constant of at most 10 nM.
25. A multiplexed immunoreagent composition comprising a plurality of the immunoreagent compositions of claim 1 .
26. The multiplexed immunoreagent composition of claim 25 , wherein the composition comprises at least three of the immunoreagent compositions.
27. The multiplexed immunoreagent composition of claim 25 , wherein the composition comprises at least five of the immunoreagent compositions.
28. The multiplexed immunoreagent composition of claim 25 , wherein the composition comprises eight of the immunoreagent compositions.